Payment overview · 2025
General Payments
$1,614.38
83 reported records · 13 companies
Healthcare provider profile · identity verified
Thomas C Mcgee, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · MOBILE, AL · NPI 1942253737
Verified facts
What the public records show
CMS Open Payments records show Thomas C Mcgee, M.D. received $1,614.38 in general payments during 2025 across 83 reported records.
ABBVIE INC. accounted for 30.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Benlysta, Farxiga, Kerendia, Otezla, Rinvoq.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 150 claims for Rinvoq by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Otezla by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Farxiga by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BENLYSTA as an associated drug or biological on 19884 records involving 5034 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Benlysta by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI as an associated drug or biological on 23185 records involving 7011 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Simponi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 28 records involving 28 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Xarelto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $491.75 | 30.5% | 23 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $369.27 | 22.9% | 24 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $265.43 | 16.4% | 12 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $116.52 | 7.2% | 6 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $104.10 | 6.5% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $61.51 | 3.8% | 3 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $60.56 | 3.8% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $46.42 | 2.9% | 3 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $21.79 | 1.4% | 1 | 2025 |
| Invivyd Inc | Unresolved — no canonical attribution shown | $20.89 | 1.3% | 1 | 2025 |
| Janssen Pharmaceuticals, Inc | Unresolved — no canonical attribution shown | $19.45 | 1.2% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $19.19 | 1.2% | 1 | 2025 |
| Fresenius Kabi USA, LLC | Unresolved — no canonical attribution shown | $17.50 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,614.38 | 83 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $361.00 | 18 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $265.43 | 12 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $157.59 | 8 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $157.59 | 8 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $130.75 | 5 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $116.52 | 6 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $115.02 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $104.10 | 4 | 2025 |
Source payment records
|
|||||
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc., Janssen Pharmaceuticals, Inc | $80.96 | 4 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $62.43 | 4 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $60.56 | 3 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $30.16 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $23.05 | 2 | 2025 |
Source payment records
|
|||||
| FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE Normalized: flublok quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE HIGH-DOSE Normalized: fluzone high dose |
Biological | SANOFI PASTEUR INC. | $21.79 | 1 | 2025 |
Source payment records
|
|||||
| PEMGARDA Normalized: pemgarda |
Biological | Invivyd Inc | $20.89 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $19.19 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $16.73 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.26 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BENLYSTA benlysta |
2025 | Benlysta | 2024 | 48 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 62 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 150 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
150 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
62 | 18 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | BENLYSTA open payments reported associated product |
CMS Open Payments — General Payments 19884 supporting records · 5034 recipient NPIs · example record 1190332353 |
Benlysta · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI open payments reported associated product |
CMS Open Payments — General Payments 23185 supporting records · 7011 recipient NPIs · example record 1174257377 |
Simponi · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 28 supporting records · 28 recipient NPIs · example record 1174296970 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Methotrexate | Methotrexate Sodium | 728 | 148 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 536 | 131 |
| Levothyroxine Sodium | Levothyroxine Sodium | 534 | 114 |
| Gabapentin | Gabapentin | 498 | 109 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 498 | 132 |
| Celecoxib | Celecoxib | 493 | 105 |
| Atorvastatin Calcium | Atorvastatin Calcium | 444 | 120 |
| Prednisone | Prednisone | 427 | 76 |
| Allopurinol | Allopurinol | 415 | 113 |
| Spironolactone | Spironolactone | 292 | 84 |
| Leflunomide | Leflunomide | 272 | 77 |
| Tramadol Hcl | Tramadol Hcl | 254 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 214 | 66 |
| Enbrel Sureclick | Etanercept | 208 | 26 |
| Omeprazole | Omeprazole | 206 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 202 | 42 |
| Methylprednisolone | Methylprednisolone | 202 | 76 |
| Meloxicam | Meloxicam | 186 | 39 |
| Losartan Potassium | Losartan Potassium | 174 | 52 |
| Jardiance | Empagliflozin | 171 | 40 |
| Carvedilol | Carvedilol | 165 | 47 |
| Amlodipine Besylate | Amlodipine Besylate | 160 | 50 |
| Zolpidem Tartrate | Zolpidem Tartrate | 153 | 29 |
| Rinvoq | Upadacitinib | 150 | 15 |
| Eliquis | Apixaban | 139 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 33 |
| Clonazepam | Clonazepam | 113 | 17 |
| Metformin Hcl Er | Metformin Hcl | 113 | 27 |
| Furosemide | Furosemide | 112 | 37 |
| Humira(Cf) Pen | Adalimumab | 100 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 99 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 98 | 27 |
| Rybelsus | Semaglutide | 98 | 19 |
| Ezetimibe | Ezetimibe | 97 | 28 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 92 | 21 |
| Mirtazapine | Mirtazapine | 92 | 26 |
| Trazodone Hcl | Trazodone Hcl | 88 | 23 |
| Montelukast Sodium | Montelukast Sodium | 87 | 21 |
| Famotidine | Famotidine | 84 | 26 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 81 | 12 |
| Folic Acid | Folic Acid | 80 | 23 |
| Simvastatin | Simvastatin | 80 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 76 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 73 | 18 |
| Bupropion Xl | Bupropion Hcl | 70 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 69 | 21 |
| Probenecid-Colchicine | Probenecid/Colchicine | 69 | 13 |
| Azithromycin | Azithromycin | 68 | 50 |
| Colchicine | Colchicine | 68 | 16 |
| Alendronate Sodium | Alendronate Sodium | 67 | 21 |
| Tamsulosin Hcl | Tamsulosin Hcl | 67 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 66 | 17 |
| Sertraline Hcl | Sertraline Hcl | 65 | 19 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 64 | 17 |
| Potassium Chloride | Potassium Chloride | 63 | 23 |
| Buspirone Hcl | Buspirone Hcl | 62 | 17 |
| Farxiga | Dapagliflozin Propanediol | 62 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 62 | 14 |
| Topiramate | Topiramate | 61 | 15 |
| Actemra Actpen | Tocilizumab | 54 | suppressed |
| Enbrel Mini | Etanercept | 52 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 50 | 17 |
| Benlysta | Belimumab | 48 | suppressed |
| Metformin Hcl | Metformin Hcl | 48 | 17 |
| Nortriptyline Hcl | Nortriptyline Hcl | 48 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 47 | 15 |
| Pentoxifylline | Pentoxifylline | 47 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 46 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 44 | suppressed |
| Pioglitazone-Metformin | Pioglitazone Hcl/Metformin Hcl | 44 | 11 |
| Pregabalin | Pregabalin | 43 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 42 | suppressed |
| Kevzara | Sarilumab | 42 | suppressed |
| Xeljanz | Tofacitinib Citrate | 42 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 40 | 17 |
| Cefdinir | Cefdinir | 39 | 34 |
| Finasteride | Finasteride | 39 | suppressed |
| Lisinopril | Lisinopril | 39 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 38 | 19 |
| Alprazolam | Alprazolam | 37 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 36 | suppressed |
| Repaglinide | Repaglinide | 36 | suppressed |
| Ursodiol | Ursodiol | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Irbesartan | Irbesartan | 34 | suppressed |
| Etodolac | Etodolac | 33 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 33 | suppressed |
| Baclofen | Baclofen | 32 | suppressed |
| Repatha Sureclick | Evolocumab | 32 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 31 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 31 | suppressed |
| Tacrolimus | Tacrolimus | 30 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 29 | 28 |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Acetazolamide | Acetazolamide | 27 | suppressed |
| Acyclovir | Acyclovir | 27 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 26 | 11 |
| Synthroid | Levothyroxine Sodium | 26 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 21 |
| Nitroglycerin Patch | Nitroglycerin | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Calcitriol | Calcitriol | 24 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 24 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 23 | suppressed |
| Kerendia | Finerenone | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Sulfasalazine | Sulfasalazine | 22 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Cilostazol | Cilostazol | 21 | suppressed |
| Eplerenone | Eplerenone | 21 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 21 | suppressed |
| Nadolol | Nadolol | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 20 | suppressed |
| Cephalexin | Cephalexin | 19 | 16 |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 15 |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Belsomra | Suvorexant | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Atenolol | Atenolol | 17 | suppressed |
| Cinacalcet Hcl | Cinacalcet Hcl | 17 | suppressed |
| Etodolac Er | Etodolac | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Simponi | Golimumab | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Cimzia (2 Pack) | Certolizumab Pegol | 16 | suppressed |
| Dexamethasone | Dexamethasone | 16 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 16 | suppressed |
| Otezla | Apremilast | 16 | suppressed |
| Zaleplon | Zaleplon | 16 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 15 | suppressed |
| Ramelteon | Ramelteon | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 14 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 14 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 14 | suppressed |
| Humira Pen | Adalimumab | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Januvia | Sitagliptin Phosphate | 14 | suppressed |
| Sulindac | Sulindac | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Olanzapine | Olanzapine | 13 | suppressed |
| Rayos | Prednisone | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Movantik | Naloxegol Oxalate | 12 | suppressed |
| Sotalol Af | Sotalol Hcl | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 11 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 11 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 11 | suppressed |
| Taltz Autoinjector | Ixekizumab | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,614.38 · 83 records | ABBVIE INC. | BENLYSTA, Bimzelx, ENBREL, EVENITY, FARXIGA, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, FLUZONE HIGH-DOSE, KRYSTEXXA, Kerendia, LUPKYNIS, OTEZLA, PEMGARDA, PROLIA, RINVOQ, SAPHNELO, SKYRIZI, TAVNEOS, TREMFYA, Tymlos, UPLIZNA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Benlysta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error